Literature DB >> 2610502

Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.

K M Deppermann1, H Lode, G Höffken, G Tschink, C Kalz, P Koeppe.   

Abstract

Two randomized double-blind crossover studies and one randomized crossover study were performed to document possible drug-drug interactions between antacids (aluminum magnesium hydroxide, 10 ml per dose for 10 doses), antimuscarinic drugs (pirenzepine, 50 mg per dose for 4 doses), and H2-blockers (ranitidine, 150 mg per dose for 3 doses) and amoxicillin (1,000 mg), cephalexin (1,000 mg), doxycycline (200 mg), and amoxicillin-clavulanic acid (625 mg). Ten healthy volunteers participated in each study. Concentrations in serum and urine were measured by bioassay, and pharmacokinetic parameters were calculated by the usual open one- or two-compartment models (statistics were determined by the Wilcoxon test). The antacid, pirenzepine, and ranitidine had no influence on the bioavailability of amoxicillin, cephalexin, and amoxicillin-clavulanic acid. Only small differences could be observed in the pharmacokinetic parameters, but they are not of therapeutic importance. However, the antacid caused a significant (P less than 0.01) reduction in the gastrointestinal absorption of doxycycline (area under the concentration-time curve, 38.6 +/- 22.7 mg.h/liter, fasting; 6.0 +/- 3.2 mg.h/liter, with antacid), resulting in subtherapeutic levels of doxycycline.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2610502      PMCID: PMC172785          DOI: 10.1128/AAC.33.11.1901

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

Review 1.  Clinical pharmacokinetics (second of two parts).

Authors:  D J Greenblatt; J Koch-Weser
Journal:  N Engl J Med       Date:  1975-11-06       Impact factor: 91.245

2.  Avidity of terramycin and aureomycin for metallic cations.

Authors:  A ALBERT
Journal:  Nature       Date:  1953-08-01       Impact factor: 49.962

3.  Reduced enteral absorption of ciprofloxacin in the presence of antacids.

Authors:  G Höffken; K Borner; P D Glatzel; P Koeppe; H Lode
Journal:  Eur J Clin Microbiol       Date:  1985-06       Impact factor: 3.267

4.  Blood levels and management of lithium treatment.

Authors:  J L Crammer; R M Rosser; G Crane
Journal:  Br Med J       Date:  1974-09-14

5.  Decrease of tetracycline absorption in man by sodium bicarbonate.

Authors:  W H Barr; J Adir; L Garrettson
Journal:  Clin Pharmacol Ther       Date:  1971 Sep-Oct       Impact factor: 6.875

6.  Comparison of in vitro activity and clinical pharmacology of doxycycline with other tetracyclines.

Authors:  J E Rosenblatt; J E Barrett; J L Brodie; W M Kirby
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

7.  Cephalexin: in vitro bacterial susceptibility, absorption in volunteers, and antibacterial activity of sera and urine.

Authors:  R L Perkins; H N Carlisle; S Saslaw
Journal:  Am J Med Sci       Date:  1968-08       Impact factor: 2.378

Review 8.  Interactions affecting drug absorption.

Authors:  P G Welling
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

9.  A program for non-linear regression analysis to be used on desk-top computers.

Authors:  P Koeppe; C Hamann
Journal:  Comput Programs Biomed       Date:  1980-12

10.  Ranitidine influences the uptake of oral midazolam.

Authors:  R J Elwood; P J Hildebrand; J W Dundee; P S Collier
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

View more
  18 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption.

Authors:  M Boeckh; H Lode; G Höffken; S Daeschlein; P Koeppe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

3.  Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.

Authors:  Gabriela Grunder; Yvonne Zysset-Aschmann; Florence Vollenweider; Thomas Maier; Stephan Krähenbühl; Juergen Drewe
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Outcome of intravenous azithromycin therapy in patients with complicated scrub typhus compared with that of doxycycline therapy using propensity-matched analysis.

Authors:  Mi-Ok Jang; Hee-Chang Jang; Uh Jin Kim; Joon Hwan Ahn; Seung-Ji Kang; Sook-In Jung; Hee-Young Shin; Kyung-Hwa Park
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

Review 5.  Clinically significant drug interactions with antacids: an update.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

6.  A limited number of prescribed drugs account for the great majority of drug-drug interactions.

Authors:  Johan Holm; Birgit Eiermann; Erik Eliasson; Buster Mannheimer
Journal:  Eur J Clin Pharmacol       Date:  2014-09-06       Impact factor: 2.953

7.  Quantitative PCR and in vivo efficacy of antibiotics in the treatment of Vibrio vulnificus infection in a mouse model.

Authors:  G P Neupane; D-M Kim; N R Yun; S-H Shin; S-C Lim; C-H Choi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-21       Impact factor: 3.267

8.  Multiple-dose pharmacokinetics of ceftibuten in healthy volunteers.

Authors:  C Lin; E Radwanski; M Affrime; M N Cayen
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 9.  Fluoroquinolones: interaction profile during enteral absorption.

Authors:  K M Deppermann; H Lode
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.

Authors:  N Saathoff; H Lode; K Neider; K M Depperman; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.